Comparison

Myelin Basic Protein (MBP) (68-82), guinea pig

Item no. CS-0025318-10mg
Manufacturer ChemScene
Amount 10mg
Category
Type Molecules
Specific against other
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Similar products 98474-59-0
Available
CAS
98474-59-0
Purity
>98%
Formula
C71H113N23O28
MWt
1736.79
Solubility
H2O
Clinical Information
No Development Reported
Pathway
Others
Target
Others
Biological Activity
Myelin Basic Protein (MBP) (68-82), guinea pig is a fragment of myelin basic protein (MBP). In Vitro: Multiple sclerosis is the most common autoimmune disorder affecting the central nervous system. In this study, whole blood samples are analyzed for activation capacity and the activatability of CD4+ and CD8+ T-lymphocytes by human total myelin basic protein (MBP), human MBP 104-118 fragment, and guinea pig MBP (68-82) fragment. A significant increase in the number of activated T-lymphocytes was observed in the whole blood. For all three tested MBPs, this increase in activated CD4+ and CD8+ T-lymphocytes is statistically significant (p<0.01). However, this increase in activated T-cells is most prominent following incubation with human total MBP, followed by human 104-118 fragment; the smallest increase is observed following incubation with guinea pig MBP (68-82) fragment (human total MBP>huMBP-104-118>guinea pig MBP (68-82))[1]. In Vivo: Whether pretreatment with bee venom acupuncture (BVA) from the same day of MBP (68-82) immunization can affect the induction and progression of experimental autoimmune encephalomyelitis (EAE) and weight loss is examined. At 5-9 days after immunization, rats in the myelin basic protein (MBP) group start displaying partial loss of tail tonus (clinical signs, 0.5) in a freely moving environment. At 10-16 days after immunization, most of the rats in the MBP group display more severe symptoms of neurological deficit including paraparesis of the hindlimb, paraplegia, tetraparesis, and tetraplegia. In contrast, rats in the MBP?+?BVA group display relatively slight neurological deficits in a dose-dependent manner at 11-15 days after immunization, compared to the rats in the MBP group. The onset of symptoms is slightly delayed (BVA 0.8 mg/kg, 6.4+/-0.6 days) and the maximal clinical score is markedly decreased (BVA 0.25 mg/kg, 3.7+/-0.2; BVA 0.8 mg/kg, 2.8+/-0.3), compared to that in the MBP group. At this time, the mean body weight of rats in the MBP group is decreased as compared to that of rats in the normal group, but it is significantly increased in rats of the MBP?+?BVA group as compared to rats in the MBP group[2].

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close